Clinical Trials Browser

Breast Neoplasms

NCT02883062 2026-04-13

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Phase 2 Active not recruiting

67 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06704659 2026-03-09

RAY-no-BAN

Phase NA Recruiting

60 enrolled

Breast

Breast Neoplasms, Recurrence

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

Phase 2 Recruiting

162 enrolled

Breast

Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

84 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

200 enrolled

Breast

Breast Neoplasms

NCT01796197 2026-02-05

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Phase 2 Completed

23 enrolled 10 charts

Breast

Breast Neoplasms

NCT06092892 2025-12-10

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

Phase 2 Recruiting

45 enrolled

Breast

Breast Neoplasms, Lymphedema

NCT00210236 2025-10-20

AXIL95

Phase 3 Terminated

625 enrolled 8 charts

Breast

Breast Neoplasms

NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Phase NA Not yet recruiting

1,039 enrolled

Breast

Breast Neoplasms

NCT06839001 2025-06-26

CRYSTAL - SIX

Phase 3 Recruiting

750 enrolled

Breast

Breast Neoplasms

NCT06817954 2025-02-10

To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer

Phase NA Recruiting

800 enrolled

Breast

Breast Neoplasms

NCT05440149 2024-11-29

PORT-N1

Phase 3 Recruiting

1,106 enrolled

Breast

Breast Neoplasms

NCT06415032 2024-10-21

BE-Quilt

Phase NA Recruiting

296 enrolled

Breast

Breast Neoplasms, Pain

NCT01618357 2024-05-22

Pre-Operative Radiation and Veliparib for Breast Cancer

Phase 1 Completed

19 enrolled

Breast

Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

Phase 2 Terminated

5 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03514654 2021-05-18

MIAMI

Phase NA Completed

4 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms

NCT04729647 2021-02-02

Immature Granulocyte Count and Delta Neutrophil Index Factors for Axillary Metastasis of Breast Cancer

Phase NA Completed

83 enrolled

Breast

Breast Neoplasms

NCT00574587 2020-10-14

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Phase 1/2 Completed

55 enrolled 10 charts

Breast

Breast Neoplasms

NCT01901146 2019-08-07

Lilac

Phase 3 Completed

725 enrolled 18 charts

Breast

Breast Neoplasms

NCT03627442 2018-08-13

Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction

Phase NA Unknown

15 enrolled

Breast

Breast Neoplasms

NCT02061527 2018-04-24

Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment

Phase NA Completed

135 enrolled

Breast

Breast Neoplasms

NCT02953184 2017-12-29

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Phase 2 Unknown

160 enrolled

Breast

Breast Neoplasms

NCT02673268 2017-10-12

MARCI

Phase 2 Unknown

80 enrolled

Breast

Breast Neoplasms

NCT01167192 2016-12-30

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

Phase 2 Terminated

10 enrolled 8 charts

Breast

Breast Neoplasms

NCT00603408 2016-08-19

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Phase 2 Terminated

5 enrolled 7 charts

Breast

Breast Neoplasms

NCT02464774 2015-06-08

Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer

Phase NA Unknown

464 enrolled

Breast

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT00574301 2013-07-25

Percutaneous Removal and Margin Ablation for Breast Cancer

Phase 1/2 Completed

32 enrolled

Breast

Breast Neoplasms

NCT00656604 2013-03-05

Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics

Phase NA Completed

30 enrolled

Breast

Breast Neoplasms

NCT01199354 2011-06-09

M-RIC

Phase 2 Unknown

80 enrolled

Breast

Breast Neoplasms

Clinical Trials

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

RAY-no-BAN

A Study of Surgery and Radiotherapy in People With Breast Cancer

NoCUT-BC

PETREMAC

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

AXIL95

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

CRYSTAL - SIX

To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer

PORT-N1

BE-Quilt

Pre-Operative Radiation and Veliparib for Breast Cancer

0927GCC

MIAMI

Immature Granulocyte Count and Delta Neutrophil Index Factors for Axillary Metastasis of Breast Cancer

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Lilac

Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction

Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

MARCI

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer

Percutaneous Removal and Margin Ablation for Breast Cancer

Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics

M-RIC